Pediatric CNS Focus Lysogene's lead programs target pediatric neurodegenerative lysosomal storage disorders, offering strong opportunities to partner with pediatric neurology centers, lysosomal disease networks, and patient advocacy groups for trial site identification, patient recruitment, and co-development planning.

Strategic Partnership Potential A proven collaboration with Sarepta demonstrates readiness for co-development, licensing, or co-funding deals; engage other gene therapy developers, CROs/CDMOs and pharma to explore partnerships that accelerate development while sharing risk.

European Access Advantage France-based operations with EU regulatory familiarity provide a compelling angle for regional collaborations, enabling access to European talent, funding channels, and cross-border trial execution in pediatric gene therapy.

Development Expertise Lysogene offers end-to-end development capabilities from discovery to registration, making it attractive for partners seeking turnkey programs including regulatory strategy, manufacturing planning, and clinical trial execution.

Funding Backing Signals Strong investor support and fundraising momentum signal credibility and can support milestone-driven partnerships or co-investment models; discuss opportunities for collaborative funding and early-stage programs.